



CNMV  
Markets Directorate General  
C/ Edison núm. 4  
28006 Madrid

Madrid, June 1, 2026

In accordance with the provisions of article 226 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following:

### **INSIDE INFORMATION**

Pharma Mar, S.A. announces that the European Commission (EC) has approved the combination of Zepzelca® (lurbinectedin) with atezolizumab (Tecentriq®) as a first-line maintenance treatment for adult patients with extensive-stage small cell lung cancer (SCLC), whose disease has not progressed following standard induction therapy.

This approval follows the positive opinion issued on March 27, 2026, by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) concerning this treatment (communication of Inside Information with registry number 3155).

Please find attached press release that will be distribute to the media.

**Pharma Mar S.A.**  
**Avda. de los Reyes, 1**  
**P.I. La Mina**  
**28770 Colmenar Viejo**  
**(Madrid) Spain**  
**[www.pharmamar.com](http://www.pharmamar.com)**

## The European Commission approves PharmaMar's Zepzelca® (lurbinectedin) for the treatment of extensive-stage small cell lung cancer in combination with atezolizumab

- The approval follows a positive opinion from the European Medicines Agency (EMA) regarding the combination of Zepzelca® (lurbinectedin) with immunotherapy, atezolizumab (Tecentriq®) as first-line maintenance therapy for this highly aggressive disease.
- The approval is based on the results of the IMforte Phase 3 trial, which showed a 46% reduction in the risk of disease progression or death and a 27% reduction in the risk of death compared to atezolizumab monotherapy.
- In Europe, around 62,000 new cases of small cell lung cancer are diagnosed each year, and this is the most aggressive type of lung cancer, characterized by rapid growth and early spread.

**Madrid, June 1<sup>st</sup>, 2026.-** PharmaMar (MSE: PHM), has announced today that the European Commission (EC) has approved the combination of Zepzelca® (lurbinectedin) with atezolizumab (Tecentriq®) as a first-line maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC), whose disease has not progressed following standard induction therapy. This approval follows the positive opinion issued on March 27<sup>th</sup> by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) concerning this treatment.

Luis Mora, Managing Director of PharmaMar, points out that *"it is great news that European patients and doctors now have access to a new treatment for this type of cancer. We believe it has the potential to change the paradigm of treatment for this disease, so we are looking forward to it being available soon in hospitals across Europe."*

The approval is based on data from the Phase 3 IMforte trial, sponsored by Roche in collaboration with Jazz Pharmaceuticals, in which the combination of lurbinectedin and atezolizumab as maintenance treatment in first-line ES-SCLC was associated with a 46% reduction in the risk of disease progression or death and a 27% reduction in the risk of death compared with atezolizumab monotherapy.

In addition, lurbinectedin has been approved as an orphan drug, a designation granted by the EMA to medicines intended for the treatment of rare or uncommon diseases affecting fewer than 5 people per 10,000 inhabitants in the European Union.

Each year, around 62,000 new cases of SCLC<sup>1</sup> are diagnosed in Europe, with most patients presenting advanced disease at the time of diagnosis<sup>2</sup>.

Lurbinectedin in combination with atezolizumab has already been approved in 13 other countries, including the United States, for first-line maintenance treatment of this disease.

#### **Legal warning**

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

#### **About PharmaMar**

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

PharmaMar has developed and now commercializes Yondelis® in Europe by itself. In addition, Zepzelca® (lurbinectedin), in the US and other countries; and Aplidin® (plitidepsin), in Australia, each with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: PM534 and PM54.

---

<sup>1</sup> Cancer today. <https://gco.iarc.who.int/today/en/fact-sheets-populations#regions>

<sup>2</sup> General information on small cell lung cancer. [Small Cell Lung Cancer Treatment \(PDQ®\) - NCI](#)

Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi) and contract-manufacturing (CDMO) of oligonucleotides. For more information, please visit: [www.pharmamar.com](http://www.pharmamar.com).

**About Zepzelca®**

Zepzelca® (lurbinectedin), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt Ecteinascidia turbinata. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Tecentriq (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.

**Media Contact:**

Lara Vadillo – Communications director [lvadillo@pharmamar.com](mailto:lvadillo@pharmamar.com)  
Phone: +34 918466000

**Capital Markets & Investor Relations:**

José Luis Moreno– VP Capital Markets & Investor Relations  
Natalia Amo – Capital Markets & Investor Relations  
[investorrelations@pharmamar.com](mailto:investorrelations@pharmamar.com)  
Phone: +34 914444500



Or please visit our website at [www.pharmamar.com](http://www.pharmamar.com)